TY - JOUR
T1 - Anxiety symptoms and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort
T2 - A cross-sectional study
AU - Scleroderma Patient-centered Intervention Network Investigators
AU - Provencher, Sabrina
AU - Carrier, Marie Eve
AU - Virgili-Gervais, Gabrielle
AU - Golberg, Meira
AU - Henry, Richard S.
AU - Kwakkenbos, Linda
AU - Fortuné, Catherine
AU - Gietzen, Amy
AU - Gottesman, Karen
AU - Guillot, Geneviève
AU - Lawrie-Jones, Amanda
AU - Sauvé, Maureen
AU - Bartlett, Susan J.
AU - Hummers, Laura K.
AU - Malcarne, Vanessa
AU - Mayes, Maureen D.
AU - Richard, Michelle
AU - Stempel, James
AU - Wojeck, Robyn K.
AU - Mouthon, Luc
AU - Benedetti, Andrea
AU - Thombs, Brett D.
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Oxford University Press on behalf of the British Society for Rheumatology.
PY - 2025/12/1
Y1 - 2025/12/1
N2 - Objective We (1) compared anxiety symptom levels in a multinational SSc cohort to a general population normative sample and (2) evaluated sociodemographic, lifestyle and SSc disease factors associated with symptoms. Methods Scleroderma Patient-centered Intervention Network Cohort participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Version 2 4a Anxiety domain upon enrolment. PROMIS domain scores use T-scores (mean = 50, S.D. = 10) calibrated to a United States normative sample. We compared T-scores to the PROMIS United States normative sample and, in SSc, assessed associations of sociodemographic, lifestyle and physician-reported disease-related variables with multivariable linear regression. Results Among 2463 participants with SSc, mean anxiety symptom T-score (52.6, S.D. = 10.0, 95% CI 52.2, 53.0) was ∼1/3 S.D. higher than the United States general population mean of 50 (S.D. = 10), though within normal limits. Higher T-scores were associated with younger age (1.07 T-score points per 10 years, 95% CI 0.74, 1.40), female sex (1.81, 95% CI 0.63, 3.00), non-married status (0.99, 95% CI 0.14, 1.84), race or ethnicity other than White (1.79, 95% CI 0.72, 2.85), living in Canada (1.70, 95% CI 0.61, 2.79), the United Kingdom (1.53, 95% CI 0.06, 2.99) or France (2.01, 95% CI 0.98, 3.03) (vs the United States), higher BMI (0.11, 95% CI 0.03, 0.17), less time since non-Raynaud's symptom onset (0.82 per 10 years, 95% CI 0.40, 1.30), gastrointestinal involvement (2.70, 95% CI 1.52, 3.88), moderate small joint contractures (1.24, 95% CI 0.10, 2.38), the absence of interstitial lung disease (0.93, 95% CI -1.79, -0.07) and Sjögren disease (1.67, 95% CI 0.17, 3.17). Interstitial lung disease was not statistically significant when accounting for an interaction with country. Anxiety was also associated with pruritus and pain intensity in a sensitivity analysis that included variables with possible bi-directional pathways with anxiety. Conclusion Anxiety symptoms were somewhat elevated among individuals with SSc and associated with multiple sociodemographic and disease factors.
AB - Objective We (1) compared anxiety symptom levels in a multinational SSc cohort to a general population normative sample and (2) evaluated sociodemographic, lifestyle and SSc disease factors associated with symptoms. Methods Scleroderma Patient-centered Intervention Network Cohort participants completed the Patient-Reported Outcomes Measurement Information System (PROMIS) Version 2 4a Anxiety domain upon enrolment. PROMIS domain scores use T-scores (mean = 50, S.D. = 10) calibrated to a United States normative sample. We compared T-scores to the PROMIS United States normative sample and, in SSc, assessed associations of sociodemographic, lifestyle and physician-reported disease-related variables with multivariable linear regression. Results Among 2463 participants with SSc, mean anxiety symptom T-score (52.6, S.D. = 10.0, 95% CI 52.2, 53.0) was ∼1/3 S.D. higher than the United States general population mean of 50 (S.D. = 10), though within normal limits. Higher T-scores were associated with younger age (1.07 T-score points per 10 years, 95% CI 0.74, 1.40), female sex (1.81, 95% CI 0.63, 3.00), non-married status (0.99, 95% CI 0.14, 1.84), race or ethnicity other than White (1.79, 95% CI 0.72, 2.85), living in Canada (1.70, 95% CI 0.61, 2.79), the United Kingdom (1.53, 95% CI 0.06, 2.99) or France (2.01, 95% CI 0.98, 3.03) (vs the United States), higher BMI (0.11, 95% CI 0.03, 0.17), less time since non-Raynaud's symptom onset (0.82 per 10 years, 95% CI 0.40, 1.30), gastrointestinal involvement (2.70, 95% CI 1.52, 3.88), moderate small joint contractures (1.24, 95% CI 0.10, 2.38), the absence of interstitial lung disease (0.93, 95% CI -1.79, -0.07) and Sjögren disease (1.67, 95% CI 0.17, 3.17). Interstitial lung disease was not statistically significant when accounting for an interaction with country. Anxiety was also associated with pruritus and pain intensity in a sensitivity analysis that included variables with possible bi-directional pathways with anxiety. Conclusion Anxiety symptoms were somewhat elevated among individuals with SSc and associated with multiple sociodemographic and disease factors.
KW - PROMIS-29
KW - SSc
KW - anxiety
KW - scleroderma
UR - https://www.scopus.com/pages/publications/105023684229
UR - https://www.scopus.com/pages/publications/105023684229#tab=citedBy
U2 - 10.1093/rheumatology/keaf374
DO - 10.1093/rheumatology/keaf374
M3 - Article
C2 - 40802523
AN - SCOPUS:105023684229
SN - 1462-0324
VL - 64
SP - 6268
EP - 6277
JO - Rheumatology
JF - Rheumatology
IS - 12
ER -